- Ondine Biomedical Inc. NPV (CDI)
- 13 August 2025 14:50:54
Source: Sharecast
The AIM-traded firm said the pilot would target reducing surgical site infections and healthcare-associated infections in orthopaedic and neurosurgery patients.
“The Mexican market is a key pillar of our long-term strategic growth plans, and we are thrilled to partner with a world-class institution in ABC Medical Center,” said chief executive Carolyn Cross.
“Their dedication to clinical excellence and patient safety makes them the ideal pilot partner for Steriwave’s initiation in Mexico.”
Ondine said Mexico’s private healthcare sector, comprising around 3,000 hospitals and performing about a quarter of all surgeries in the country, faced SSI rates nearly double those in the US, compounded by rising antimicrobial resistance.
Dra. Roxana Trejo Gonzalez, ABC’s director of infection control, said piloting Steriwave “reflects our commitment to adopting evidence-based interventions against antimicrobial resistance. Reducing nasal pathogen load is a crucial step in preventing SSIs and protecting our local and international patients.”
Steriwave, already used in hospitals in Canada, the UK and other markets, was described by Ondine as a non-antibiotic, light-activated therapy that decolonises nasal passages - a primary reservoir for multidrug-resistant organisms - without contributing to antimicrobial resistance.
At 1400 BST, shares in Ondine Biomedical were up 7.41% at 14.5p.
Reporting by Josh White for Sharecast.com.
